C4X Discovery sells Orexin-1 drug candidate to Indivior for £15.95 million
LONDON, UK: C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, today announced the execution of an asset purchase agreement for Indivior PLC (LSE: INDV) to acquire the proprietary rights to C4XD’s oral Orexin-1 receptor antagonist, C4X_3256 (INDV-2000)…